Parabilis achieves 72.2% ORR for zolucatetide in desmoid tumors
Parabilis reported updated Phase 1/2 data showing strong efficacy in desmoid tumors and secured FDA alignment for its upcoming Phase 3 trial. With $1.1 billion in cash, the company expects to fund operations through 2030.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed